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Abstract Treatment of HepG2 cells with forskolin led to 60^
100% stimulation of system A activity, measured as the Na+-
dependent uptake of K-(methylamino)isobutyric acid. The
stimulation was reproducible with cholera toxin and dibutyryl
cAMP, and inhibitable by H7, a non-specific protein kinase
inhibitor. The stimulatory effect was eliminated by cyclohex-
imide and actinomycin D. The forskolin effect was associated
with an increase in the maximal velocity of the transport system,
with no change in substrate affinity. These cells express three
different subtypes of system A (ATA1, ATA2, and ATA3).
Treatment with forskolin increased the steady-state levels of
ATA1 and ATA2 mRNAs, but decreased that of ATA3
mRNA. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
System A is an amino acid transport system that mediates
Na-coupled transport of neutral amino acids [1,2]. The func-
tional activity of this transport system is usually studied using
K-(methylamino)isobutyric acid (MeAIB) as the model sub-
strate. Recent cloning studies have revealed that system A
actually consists of more than one subtype. Three di¡erent
transporters have been cloned that have the ability to mediate
the Na-coupled transport of MeAIB. They are ATA1 [3,4],
ATA2 [5^8], and ATA3 [9,10]. ATA1 and ATA2 interact with
MeAIB with a Kt value of V0.5 mM whereas ATA3 exhibits
a Kt value for this system A model substrate in the range of 6^
10 mM. The three subtypes of system A markedly di¡er in
their tissue expression pattern. ATA1 is expressed primarily in
the brain and placenta, ATA2 is expressed in almost every
tissue, and ATA3 is expressed almost exclusively in the liver.
System A has been shown to be regulated by hormones [11^
13]. In the liver, glucagon upregulates the activity of system A
through elevation of intracellular levels of cAMP. These reg-
ulatory studies have been done prior to our current knowledge
that system A actually consists of di¡erent subtypes. There-
fore, it becomes necessary now to investigate the involvement
of the speci¢c subtypes of system A in the stimulatory action
of cAMP. Towards this goal, we studied the e¡ect of cAMP
on the activity of system A in the human liver cell line
HepG2. Even though normal liver expresses predominantly
ATA2 and ATA3, the HepG2 liver cell line expresses all three
subtypes of system A. In the present study, we analyzed the
in£uence of cAMP on the expression of each of these subtypes
of system A in this cell line.
2. Materials and methods
2.1. Materials
The HepG2 human hepatocarcinoma cell line was purchased from
the American Type Culture Collection (Manassas, VA, USA). Culture
media (minimum essential medium Eagle with Earle’s salts and L-
glutamine) was obtained from Mediatech, Inc. (Herndon, VA,
USA). Penicillin, streptomycin, and trypsin were obtained from Life
Technologies, Inc. (Rockville, MD, USA). Fetal bovine serum, for-
skolin, cholera toxin, dibutyryl cAMP, cycloheximide, actinomycin D
and H7 were from Sigma (St. Louis, MO, USA). [14C]MeAIB (speci¢c
radioactivity, 50 mCi/mmol) was purchased from American Radio-
labeled Chemicals (St. Louis, MO, USA). L-[3H]Glutamic acid (spe-
ci¢c radioactivity, 24 Ci/mmol), L-[3H]tryptophan (speci¢c radioactiv-
ity, 32 Ci/mmol), and L-[3H]arginine (speci¢c radioactivity, 54 Ci/
mmol) were purchased from Amersham Pharmacia Biotech Inc. (Pis-
cataway, NJ, USA).
2.2. Culture of HepG2 cells
The cells were cultured as described in the protocol provided by
ATCC. The culture medium (minimum essential medium Eagle with
Earle’s salts and L-glutamine) was supplemented with 10% fetal bo-
vine serum, penicillin (100 units/ml), streptomycin (100 Wg/ml) and
sodium pyruvate (1 mM). Trypsin-released cells were seeded in colla-
gen-coated 24-well plates at a density of 1U105 cells/well and allowed
to grow as a monolayer. 24 h after subculturing, the medium was
replaced with fresh medium that did not contain fetal bovine serum
(treatment medium). Treatment with di¡erent reagents was carried
out for indicated time periods in this treatment medium prior to
uptake measurements.
2.3. Uptake measurements in cells
The culture medium was removed by aspiration, and the cells were
washed once with the uptake bu¡er. 0.25 ml of uptake bu¡er con-
taining radiolabeled substrate (MeAIB, glutamic acid, tryptophan or
arginine) was added to the wells and incubated for 10 min at 37‡C.
Uptake was terminated by aspirating the bu¡er and subsequently
washing the cells twice with fresh uptake bu¡er. The cells were then
lysed with 0.5 ml of 1% SDS in 0.2 N NaOH, and the lysate was
transferred to scintillation vials for quantitation of radioactivity. The
composition of the uptake bu¡er was 25 mM HEPES^Tris (pH 8.5),
140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl, 0.8 mM MgSO4, 5 mM
glucose. Concentration of MeAIB in most uptake experiments was
0.5 mM. Carrier-mediated uptake of MeAIB was calculated by sub-
tracting the uptake measured in the presence of an excess amount of
L-alanine (10 mM) from the total uptake measured in the absence of
L-alanine.
2.4. Isolation of poly(A)+ RNA and Northern analysis
Total RNA was isolated from control and treated HepG2 cells
using Trizol reagent (Life Technologies), and then poly(A) RNA
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was isolated from the total RNA by a⁄nity chromatography using
oligo(dT) cellulose (Life Technologies). The poly(A) RNA samples
were size-fractionated on a denaturing formaldehyde-agarose gel and
probed with 32P-labeled human ATA1 [4], human ATA2 [8] or human
ATA3 [10] cDNA or human glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) cDNA. The cDNAs were labeled with [K-32P]dCTP
using the ready-to-go oligolabeling kit (Amersham Pharmacia Biotech
Inc.). The relative abundance of ATA1, ATA2 or ATA3 mRNA was
determined using the following formula: (a/b)/(c/d) where a is the
densitometric value (in arbitrary units) of ATA1, ATA2 or ATA3
mRNA band in cells treated with forskolin, b is the densitometric
value of the GAPDH mRNA band in cells treated with forskolin, c
is the densitometric value of ATA1, ATA2 or ATA3 mRNA band in
control cells, and d is the densitometric value of the GAPDH mRNA
band in control cells. The relative ATA1, ATA2 or ATA3 mRNA
abundance in control cells (c/d) was taken as 1 and the abundance of
ATA1, ATA2 or ATA3 mRNA in cells treated with forskolin was
expressed in relation to this control value.
3. Results
Forskolin and cholera toxin are the two agents that are
widely used to increase intracellular levels of cAMP in mam-
malian cells. Therefore, we ¢rst assessed the in£uence of for-
skolin treatment on the transport activity of the amino acid
transport system A in HepG2 cells. Cells were treated with
100 WM forskolin for varying periods of time (2^8 h) and then
the transport of MeAIB, a speci¢c model substrate for system
A, was measured in a Na-containing medium. Treatment of
the cells with forskolin for 2 h caused a signi¢cant stimulation
(55 þ 3%) of system A transport activity (Fig. 1A). The stim-
ulatory e¡ect was only slightly increased when the treatment
time was extended to 4^8 h. The range of stimulatory e¡ect
within this time period was 55^100%. We selected 6 h as the
treatment period for subsequent studies. The in£uence of for-
skolin on system A activity was dose-dependent, with maxi-
mal stimulation observed with 30 WM forskolin (Fig. 1B). The
e¡ect of forskolin on system A was speci¢c because the trans-
port of two other amino acids (tryptophan and arginine) was
not a¡ected under similar conditions (Fig. 1C). Tryptophan is
a preferred substrate for the amino acid transport system L
and arginine is a preferred substrate for cationic amino acid
transport systems such as y, b0;, and yL [14^16]. The
uptake of glutamate, a preferred substrate for system X3AG,
was however stimulated to a signi¢cant extent by forskolin.
These data show that forskolin treatment increases the trans-
port activity of system A and X3AG, but not that of systems L,
y, b0;, and yL.
The stimulatory e¡ect of forskolin on the transport activity
of system A was reproducible with cholera toxin and dibutyryl
cAMP (Fig. 1D). Treatment of the cells with 100 ng/ml chol-
era toxin for 6 h increased the transport of MeAIB signi¢-
cantly (30 þ 2%). Under similar conditions, dibutyryl cAMP, a
cell-permeable cAMP derivative, also increased the uptake of
MeAIB to a signi¢cant extent (27 þ 1%). Since the cellular
e¡ects of cAMP are mediated principally by protein kinase
A, we tested whether the in£uence of forskolin on system A
activity can be blocked by inhibitors of protein kinases. We
used H7 for this purpose. H7 is a potent inhibitor of protein
kinase A [17]. Treatment of the cells with forskolin (100 WM)
in the absence of the protein kinase inhibitor caused an in-
crease of 60 þ 2% in the activity of system A as measured by
MeAIB transport. However, when the treatment was carried
out in the presence of 50 WM H7, the forskolin e¡ect on the
activity of system A was abolished completely (Fig. 1D), in-
dicating that the stimulatory action of forskolin is most likely
to be mediated by protein kinase A.
To assess the involvement of de novo synthesis of RNA and
protein in the e¡ect of forskolin on system A activity, we
tested the ability actinomycin D (an inhibitor of transcription)
and cycloheximide (an inhibitor of translation) to block the
e¡ect of forskolin (Fig. 2A). In the absence of these inhibitors,
treatment of the cells with forskolin (100 WM) for 4 h in-
creased MeAIB transport by 60 þ 2%. However, when the
treatment was done in the presence of actinomycin D
(5 Wg/ml) or cycloheximide (50 Wg/ml), the stimulatory e¡ect
of forskolin was abolished completely. These data show that
de novo synthesis of RNA and protein is involved in the
forskolin-induced increase in system A activity.
To determine the in£uence of forskolin on the kinetic pa-
rameters of system A, we investigated the saturation kinetics
of MeAIB transport in control cells and in forskolin-treated
Fig. 1. A: Time course of forskolin-induced e¡ect on MeAIB up-
take in HepG2 cells. Cells were treated with or without forskolin
(100 WM) for indicated time periods (2^8 h) at 37‡C, following
which MeAIB uptake was measured at a concentration of 0.5 mM
and an incubation period of 10 min. Results are given as percent of
corresponding control. B: Dose dependence of the in£uence of for-
skolin on MeAIB uptake in HepG2 cells. Cells were treated with in-
creasing concentrations of forskolin for 6 h at 37‡C, following
which the uptake of MeAIB (0.5 mM) was measured with a 10-min
incubation. C: Speci¢city of forskolin e¡ect in HepG2 cells. Cells
were treated with or without forskolin (100 WM) for 6 h at 37‡C,
following which uptake of MeAIB, L-tryptophan, L-arginine and
L-glutamic acid was measured. Final concentration of MeAIB was
0.5 mM and that of L-tryptophan, L-arginine and L-glutamic acid
was 20 WM. The incubation period for uptake was 10 min. Results
are given as percent of corresponding control. D: E¡ect of forskolin
with or without H7, cholera toxin and dibutyryl cAMP on MeAIB
uptake in HepG2 cells. Cells were treated with forskolin (100 WM)
in the presence or absence of H7 (50 WM), cholera toxin (100 ng/
ml), or dibutyryl cAMP (1 mM) for 6 h at 37‡C, following which
MeAIB uptake was measured at a concentration of 0.5 mM and an
incubation period of 10 min.
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(forskolin concentration, 100 WM; treatment time, 6 h) cells
(Fig. 2B). The transport of MeAIB was saturable in both
cases. The values for the Michaelis^Menten constant (Kt)
and the maximal velocity (Vmax) in control cells were
0.44 þ 0.04 mM and 28.2 þ 0.7 nmol/mg protein/10 min, re-
spectively. The corresponding values in forskolin-treated cells
were 0.38 þ 0.03 mM and 53.6 þ 1.0 nmol/mg protein/10 min.
Therefore, the stimulatory e¡ect of forskolin on system A
activity was primarily due to an increase in the maximal ve-
locity of the transport system with no signi¢cant change in the
substrate a⁄nity.
System A consists of at least three subtypes, known as
ATA1, ATA2, and ATA3 [3^10]. To assess the in£uence of
forskolin on the steady-state levels of mRNA speci¢c for each
of these three subtypes, we subjected the poly(A) RNA sam-
ples isolated from control cells and from forskolin-treated
(forskolin concentration, 100 WM; treatment time, 6 h) cells
to Northern blot analysis (Fig. 3). GAPDH mRNA was used
as the internal control. The presence of mRNA for all three
subtypes of system A was evident in these cells, suggesting
that all three subtypes are expressed in these cells. Treatment
with forskolin increased the steady-state mRNA levels for
ATA1 and ATA2, but decreased the steady-state mRNA level
for ATA3. There were three distinct mRNA species speci¢c
for ATA1 (9.0, 2.8, and 0.9 kb). However, forskolin increased
the steady-state levels only for 9.0-kb mRNA and 2.8-kb
mRNA. There was no change in the levels of 0.9-kb
mRNA. The increase in the 9.0-kb mRNA levels was 50%
and the increase in the 2.8-kb mRNA levels was 100%. There
was only a single mRNA species for ATA2 (4.5 kb) and for-
skolin increased the levels of this mRNA by 150%. The
ATA3-speci¢c mRNA was 4.0 kb in size and forskolin de-
creased the levels of this mRNA by 50%. These data show
that forskolin has di¡erential e¡ects on the expression of the
three subtypes of system A.
4. Discussion
This represents the ¢rst report on the in£uence of cAMP on
the expression of the amino acid transport system A at the
molecular level. Previous studies have clearly shown that the
transport activity of system A in hepatocytes is enhanced by
cAMP and that the process involves de novo synthesis of
RNA and protein [11^13]. When these studies were done, it
was not known that system A actually consists of di¡erent
subtypes. Recent data indicate that liver expresses at least
two of the three known subtypes of system A [5,8^10]. North-
ern blot analysis has provided evidence for the presence of
ATA2 mRNA and ATA3 mRNA in the liver [5,8^10]. This
is supported by our recent isolation of cDNAs for ATA2 and
ATA3 from a HepG2 cDNA library [8,10]. The mRNA for
ATA1 was not detectable in the liver by Northern hybridiza-
tion [3]. However, the present studies show that HepG2 cells
express all three subtypes of system A.
Fig. 2. A: E¡ect of actinomycin D and cycloheximide on forskolin-
induced stimulation of MeAIB uptake in HepG2 cells. Cells were
treated with or without forskolin (100 WM) in the presence of acti-
nomycin D (5 Wg/ml) or cycloheximide (50 Wg/ml) for 4 h at 37‡C.
Following the treatment, MeAIB uptake was measured at a concen-
tration of 0.5 mM and an incubation period of 10 min. B: E¡ect of
forskolin on the saturation kinetics of MeAIB uptake in HepG2
cells. Cells were treated with or without forskolin (100 WM) for 6 h
at 37‡C, following which MeAIB uptake was measured over the
MeAIB concentration range of 0.1^10 mM and with an incubation
period of 10 min. Results represent Eadie^Hofstee transformation
of the uptake data.
Fig. 3. E¡ect of forskolin on steady-state levels of ATA1, ATA2,
ATA3 and GAPDH mRNA in HepG2 cells. Cells were treated with
(lane B) or without (lane A) forskolin (100 WM) for 6 h at 37‡C.
Poly(A) RNA was isolated from control and treated cells. The
size-fractionated mRNA was probed with 32P-labeled human ATA1,
human ATA2, human ATA3 and human GAPDH cDNA by se-
quential hybridization.
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Since the identi¢cation of subtypes within system A, several
reports have appeared in the literature on the regulation of
this transport system at the molecular level [18^21]. However,
all these studies have focused on one particular subtype,
namely ATA2. The expression of ATA2 is induced by amino
acid deprivation in human ¢broblasts[18], rat C6 glioma cells
[19], and rat skeletal muscle cells [20] and also by hypertonic-
ity in human endothelial cells [21]. In all cases, the induction
is associated with a parallel increase in the steady-state levels
of ATA2 mRNA. The present report describes for the ¢rst
time the changes in the expression of all three subtypes of
system A in response to a speci¢c regulatory signal. The ac-
tivity of system A in HepG2 cells is enhanced by agents that
increase intracellular levels of cAMP as well as by a cell-per-
meable cAMP derivative. Since HepG2 cells express all three
subtypes of system A, it becomes necessary to establish the
identity of the subtype that is subject to regulation by cAMP.
The present studies show that cAMP induces the expression of
ATA1 as well as the expression of ATA2. In contrast, the
expression of ATA3 is suppressed by cAMP. Based on the
known kinetic characteristics of the three subtypes of system
A [4,8,10], we believe that the transport of MeAIB observed in
HepG2 cells is mediated predominantly by ATA1 and ATA2.
The contribution of ATA3 to the observed transport is likely
to be minimal. This is because the a⁄nity of ATA3 for
MeAIB is at least one order of magnitude lower that the
a⁄nity of ATA1 or ATA2 for the same substrate [4,8,10].
Kinetic analysis of MeAIB transport in these cells suggests
the apparent involvement of a single saturable transport pro-
cess. This is because ATA1 and ATA2 exhibit similar satura-
tion kinetics. The Michaelis^Menten constant for human
ATA1 is 0.89 þ 0.12 mM [4], a value similar to the Michae-
lis^Menten constant for human ATA2 (0.39 þ 0.05 mM) [8].
These two values are so close to each other that they cannot
be di¡erentiated by analysis of saturation kinetics. Therefore,
we conclude that the increase in MeAIB transport induced by
cAMP in HepG2 cells is due to an increase in the expression
of ATA1 as well as ATA2.
The present studies show that cAMP a¡ects di¡erentially
the expression of the three subtypes of system A. This second
messenger enhances the expression of ATA1 and ATA2 but
suppresses the expression of ATA3. ATA1 is expressed pri-
marily in the brain, placenta, and heart whereas ATA2 is ex-
pressed ubiquitously. Whether or not cAMP will have a sim-
ilar stimulatory e¡ect on the expression of ATA1 and ATA2
in all tissues expressing the two subtypes remains to be seen.
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